Sapna Syngal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/233163/publications.pdf

Version: 2024-02-01

85 papers	8,574 citations	94433 37 h-index	56724 83 g-index
87 all docs	87 docs citations	87 times ranked	9044 citing authors

#	Article	IF	Citations
1	ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. American Journal of Gastroenterology, 2015, 110, 223-262.	0.4	1,204
2	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2015, 33, 3660-3667.	1.6	603
3	Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk Individuals. Gastroenterology, 2012, 142, 796-804.	1.3	570
4	ATM Mutations in Patients with Hereditary Pancreatic Cancer. Cancer Discovery, 2012, 2, 41-46.	9.4	442
5	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society TaskÂForce on Colorectal Cancer. Gastroenterology, 2014, 147, 502-526.	1.3	397
6	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 1086-1095.	1.6	383
7	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2014, 109, 1159-1179.	0.4	363
8	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 2020, 69, 7-17.	12.1	357
9	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	9.4	282
10	BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genetics in Medicine, 2015, 17, 569-577.	2.4	231
11	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2020, 158, 1131-1153.e5.	1.3	228
12	Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology, 2015, 149, 604-613.e20.	1.3	225
13	Endoscopic Removal of Colorectal Lesionsâ€"Recommendations by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2020, 158, 1095-1129.	1.3	187
14	Prevalence and Phenotypes of APC and MUTYH Mutations in Patients With Multiple Colorectal Adenomas. JAMA - Journal of the American Medical Association, 2012, 308, 485-492.	7.4	183
15	The PREMM1,2,6 Model Predicts Risk of MLH1, MSH2, and MSH6 Germline Mutations Based on Cancer History. Gastroenterology, 2011, 140, 73-81.e5.	1.3	171
16	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society TaskÂForce on Colorectal Cancer. Gastrointestinal Endoscopy, 2020, 91, 463-485.e5.	1.0	163
17	Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome. JAMA - Journal of the American Medical Association, 2006, 296, 1469.	7.4	160
18	Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population. Cancer Prevention Research, 2011, 4, 9-22.	1.5	153

#	Article	IF	Citations
19	Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genetics in Medicine, 2019, 21, 213-223.	2.4	151
20	Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A stateâ€ofâ€theâ€science review. Cancer, 2016, 122, 2633-2645.	4.1	131
21	Development and Validation of the PREMM₅ Model for Comprehensive Risk Assessment of Lynch Syndrome. Journal of Clinical Oncology, 2017, 35, 2165-2172.	1.6	126
22	Sharing Genetic Test Results in Lynch Syndrome: Communication With Close and Distant Relatives. Clinical Gastroenterology and Hepatology, 2008, 6, 333-338.	4.4	104
23	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2020, 115, 415-434.	0.4	103
24	Inherited Colorectal Cancer Syndromes. Cancer Journal (Sudbury, Mass), 2011, 17, 405-415.	2.0	100
25	Endoscopic Removal of Colorectal Lesionsâ€"Recommendations by the US Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2020, 91, 486-519.	1.0	95
26	Colorectal Cancer in Young Adults. Digestive Diseases and Sciences, 2015, 60, 722-733.	2.3	90
27	Endoscopic Removal of Colorectal Lesions: Recommendations by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2020, 115, 435-464.	0.4	88
28	Recent advances in Lynch syndrome. Familial Cancer, 2019, 18, 211-219.	1.9	70
29	The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. Journal of Clinical Oncology, 2022, 40, 3257-3266.	1.6	69
30	Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2020, 159, 1916-1934.e2.	1.3	68
31	Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Gastroenterology, 2022, 162, 772-785.e4.	1.3	60
32	PMS2 monoallelic mutation carriers: the known unknown. Genetics in Medicine, 2016, 18, 13-19.	2.4	51
33	Comparison of the clinical prediction model PREMM_{1,2,6}and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut, 2013, 62, 272-279.	12.1	49
34	Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2014, 80, 197-220.	1.0	48
35	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	10.7	48
36	Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nature Genetics, 2019, 51, 1308-1314.	21.4	47

#	Article	IF	Citations
37	Linear-array EUS improves detection of pancreatic lesions in high-risk individuals: a randomized tandem study. Gastrointestinal Endoscopy, 2015, 82, 812-818.	1.0	43
38	Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis. New England Journal of Medicine, 2020, 383, 1028-1039.	27.0	43
39	Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2020, 18, 830-837.e1.	4.4	38
40	Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators. Genetics in Medicine, 2016, 18, 152-161.	2.4	36
41	Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2020, 92, 997-1015.e1.	1.0	35
42	Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2022, 162, 2063-2085.	1.3	35
43	Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer, 2015, 121, 3281-3289.	4.1	30
44	A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointestinal Endoscopy, 2016, 84, 115-125.e4.	1.0	30
45	Phenotypic Characteristics Associated With the <EMPH TYPE="ITAL">APC</EMPH> Gene I1307K Mutation in Ashkenazi Jewish Patients With Colorectal Polyps. JAMA - Journal of the American Medical Association, 2000, 284, 857.	7.4	29
46	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1185-1191.	2.5	29
47	Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	29
48	Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant. Cancer Prevention Research, 2021, 14, 215-222.	1.5	26
49	Community Practice Implementation of a Self-administered Version of PREMM1,2,6 to Assess Risk for Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2018, 16, 49-58.	4.4	25
50	Spotlight: US Multi-Society Task Force on Colorectal Cancer Recommendations for Follow-up After Colonoscopy and Polypectomy. Gastroenterology, 2020, 158, 1154.	1.3	23
51	Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2020, 115, 1751-1767.	0.4	22
52	Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. JCO Oncology Practice, 2021, 17, e236-e247.	2.9	22
53	Racial variation in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing. Genetics in Medicine, 2015, 17, 815-821.	2.4	21
54	Association of a let-7 miRNA binding region ofTGFBR1with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis, 2016, 37, 751-758.	2.8	16

#	Article	IF	Citations
55	Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prevention Research, 2021, 14, 1021-1032.	1.5	15
56	Patient experiences living with pancreatic cancer risk. Hereditary Cancer in Clinical Practice, 2015, 13, 13.	1.5	14
57	Comparison of Colonoscopy Quality Measures Across Various Practice Settings and the Impact of Performance Scorecards. Digestive Diseases and Sciences, 2017, 62, 894-902.	2.3	13
58	Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer. Psycho-Oncology, 2018, 27, 1711-1718.	2.3	13
59	A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. PLoS Genetics, 2019, 15, e1008344.	3.5	13
60	Surveillance of patients at high risk for colorectal cancer. Medical Clinics of North America, 2005, 89, 61-84.	2.5	12
61	A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors. Cancer Prevention Research, 2020, 13, 291-298.	1.5	12
62	Potential roles of genetic biomarkers in colorectal cancer chemoprevention. Journal of Cellular Biochemistry, 2000, 77, 28-34.	2.6	11
63	Therapy-Associated Polyposis as a Late Sequela of CancerÂTreatment. Clinical Gastroenterology and Hepatology, 2014, 12, 1046-1050.	4.4	11
64	Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Familial Cancer, 2017, 16, 377-387.	1.9	11
65	Clinical Factors Associated with Urinary Tract Cancer in Individuals with Lynch Syndrome. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 193-199.	2.5	11
66	Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome. Gastroenterology, 2021, 161, 143-150.e4.	1.3	11
67	Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2022, 117, 846-864.	0.4	11
68	Hereditary Nonpolyposis Colorectal Cancer: A Call for Attention. Journal of Clinical Oncology, 2000, 18, 2189-2192.	1.6	9
69	COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Pancreatology, 2021, 21, 1048-1051.	1.1	8
70	Biallelic Mismatch Repair Deficiency: Management and Prevention of a Devastating Manifestation of the Lynch Syndrome. Gastroenterology, 2017, 152, 1254-1257.	1.3	7
71	Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm₅ Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing. Journal of Clinical Oncology, 2020, 38, 4086-4094.	1.6	7
72	Adaptation and early implementation of the PREdiction model for gene mutations (PREMM5â„¢) for lynch syndrome risk assessment in a diverse population. Familial Cancer, 2022, 21, 167-180.	1.9	7

#	Article	IF	Citations
73	Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs). JCO Precision Oncology, 2021, 5, 808-816.	3.0	7
74	Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting. Familial Cancer, 2019, 18, 317-325.	1.9	6
75	Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access. Genetics in Medicine, 2022, 24, 1196-1205.	2.4	6
76	Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2022, 95, 1025-1047.	1.0	6
77	Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals. Familial Cancer, 2021, 20, 111-116.	1.9	5
78	Health behaviours and beliefs in individuals with familial pancreatic cancer. Familial Cancer, 2019, 18, 457-464.	1.9	4
79	ReCAP: Oncologistsâ€™ Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer. Journal of Oncology Practice, 2016, 12, 259-260.	2.5	3
80	Spotlight: US Multi-Society Task Force on Colorectal Cancer Recommendations for Endoscopic Removal of Colorectal Lesions. Gastroenterology, 2020, 158, 1130.	1.3	3
81	Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?â€”Letter. Cancer Prevention Research, 2021, 14, 973-974.	1.5	3
82	Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential. British Journal of Cancer, 2022, , .	6.4	2
83	Intercepting Pancreatic Cancer. Pancreas, 2018, 47, 1175-1176.	1.1	1
84	Reply to M.S. Daniels et al. Journal of Clinical Oncology, 2017, 35, 2588-2589.	1.6	0
85	Letter to the Editor-Recent advances in Lynch syndrome: response to MÃ¸ller et al.. Familial Cancer, 2021, 20, 121-122.	1.9	0